5 Analysts Have This to Say About EyePoint Pharmaceuticals
Portfolio Pulse from Benzinga Insights
Over the past 3 months, 5 Wall Street analysts have provided ratings for EyePoint Pharmaceuticals (NASDAQ:EYPT), with 4 being bullish and 1 somewhat bullish. The average price target is $27.6, representing an implied upside from the current price of $19.3. The target has increased by 6.15% over the past month.
December 05, 2023 | 8:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
EyePoint Pharmaceuticals has received positive ratings from analysts, with an average price target of $27.6, indicating a potential upside from the current price of $19.3.
The positive analyst ratings and the recent increase in the average price target suggest a bullish sentiment towards EYPT. This could lead to increased investor confidence and a potential short-term rise in the stock price.
CONFIDENCE 80
IMPORTANCE 85
RELEVANCE 100